Currently, out of the existing stock ratings of Mani Foroohar - 108 which are a Buy (52.17%), 82 which are a Hold (39.61%), 17 which are a Sell (8.21%)

Mani Foroohar

Work Performance Price Targets & Ratings Chart

Analyst Mani Foroohar works at LEERINK and is covering the Healthcare sector with 414 price targets and ratings displayed on 25 stocks.

Mani Foroohar's average stock forecast success ratio is 35.03% with an average time for price targets to be met of 144.24 days.

Most recent stock forecast was given on ARWR, Arrowhead Pharmaceuticals at 12-May-2023.

Wall Street Analyst Mani Foroohar

Analyst best performing recommendations are on FDMT.
The best stock recommendation documented was for FDMT at 11/14/2022. The price target of $15 was fulfilled within 1 day with a profit of $1.51 (11.19%) receiving and performance score of 111.93.

Average potential price target upside

of $39.89 (46.79%) on SRPT (SAREPTA THERAPEUTICS).
of $37.06 (25.84%) on MRNA (MODERNA).
of $16.97 (20.26%) on ALNY (ALNYLAM PHARMACEUTICALS).

ADVM Adverum Biotechnologies ALNY Alnylam Pharmaceuticals ARWR Arrowhead Pharmaceuticals BBIO BridgeBio Pharma BLUE bluebird bio CRBU DBTX DRNA Dicerna Pharmaceuticals IONS Ionis Pharmaceuticals MRNA Moderna NTLA Intellia Therapeutics RCKT Rocket Pharmaceuticals RGNX REGENXBIO RXRX WVE Wave Life Sciences Ltd SRPT Sarepta Therapeutics ABEO Abeona Therapeutics ALVR FDMT MIRM Mirum Pharmaceuticals AMYT GRPH TALS EDIT Editas Medicine BEAM Beam Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average time for PT to be met

Performance score

James Lee (MIZUHO)